BBIO
BridgeBio Pharma, Inc.
BBIO's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over BBIO overall, supported by stronger fundamentals and stronger modeled upside.
BBIO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
BBIO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BBIO PE Valuation
BBIO has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect BBIO's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
BBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.04 | +$1.17 |
| Q2 2026 | -$3.57 | +$0.55 |
| Q1 2026 | -$3.74 | -$0.18 |
| Q4 2025 | -$3.78 | -$0.90 |
| Q3 2025 | -$4.21 | -$1.79 |
| Q2 2025 | -$4.12 | -$1.48 |
| Q1 2025 | -$3.56 | -$0.33 |
| Q4 2024 | -$2.88 | +$1.07 |
BBIO is still losing money, but less than at its worst: $3.04 per share over the past year, against $4.21 at its worst in late 2025.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BBIO on earnings quality, reporting a profit while its opponent remains loss making.
BBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $353.2M | +193% |
| Q2 2026 | $243.7M | +120% |
| Q1 2026 | $194.5M | +67% |
| Q4 2025 | $154.2M | +2521% |
| Q3 2025 | $120.7M | +4318% |
| Q2 2025 | $110.6M | +5000% |
| Q1 2025 | $116.6M | -45% |
| Q4 2024 | $5.9M | +237% |
BBIO's revenue has grown year over year for six quarters in a row: $353M last quarter, up 193% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.3% | +117 points |
| Q2 2026 | -44% | +78 points |
| Q1 2026 | -54% | +35 points |
| Q4 2025 | -91% | +3752 points |
| Q3 2025 | -120% | +6898 points |
| Q2 2025 | -121% | +7975 points |
| Q1 2025 | -89% | -90 points |
| Q4 2024 | -3843% | +6324 points |
BBIO's operating margin was −3.3% last quarter, up 117 points from the same quarter a year ago, near the top of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BBIO on profitability, with a higher operating margin.
BBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$44.5M | +$65.6M |
| Q2 2026 | -$71.5M | +$9.7M |
| Q1 2026 | -$197.3M | +$1.9M |
| Q4 2025 | -$56.5M | +$138.9M |
| Q3 2025 | -$110M | +$70.7M |
| Q2 2025 | -$81.3M | -209% |
| Q1 2025 | -$199.2M | +$21M |
| Q4 2024 | -$195.4M | -$70.1M |
BBIO has burned cash in almost every quarter: −$370M over the past year, against −$586M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
BBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +244K shares |
| 1 year | +2.2% | +4.2M shares |
| 3 years | +20% | +32.7M shares |
| 5 years | +34% | +49.4M shares |
| Available history | +87% | +90.9M shares |
BBIO has 196M diluted shares, up 2.2% from a year ago, despite $253M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $42.5M |
| Q2 2026 | $127.5M |
| Q1 2026 | $82.5M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $48.3M |
| Q4 2021 | $1.5M |
BBIO spent $253M buying back its own shares over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over BBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BBIO Net Leverage
BBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.4 | Neutral |
| Stochastic | 48.6 | Neutral |
BBIO's weekly RSI is 57 (neutral) and its Stochastic is 49 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BBIO PE vs Healthcare Sector
BBIO has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $70.1 | 12% above |
| 20 week MA | $75.3 | 3.9% above |
| 50 week MA | $73.0 | 7.1% above |
| 100 week MA | $58.0 | 35% above |
| 200 week MA | $41.6 | 88% above |
BBIO is in an uptrend: it's above all five of its weekly moving averages, and 88% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
BBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.8 | $69.5 | +89% |
| 2021 | $69.5 | $40.6 | -42% |
| 2022 | $40.6 | $7.88 | -81% |
| 2023 | $7.88 | $40.4 | +412% |
| 2024 | $40.4 | $28.0 | -31% |
| 2025 | $28.0 | $75.8 | +171% |
| 2026 YTD | $75.8 | $78.2 | +3.1% |
BBIO's yearly returns have swung widely, from +412% in 2023 to −81% in 2022. It's up 3.1% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BBIO on returns for 2026, with the stronger performance.